v3.25.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2025
Mar. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,238,459 $ 2,715,411
Marketable securities (includes $1,803,035 of available-for-sale marketable securities held at fair value as of June 30, 2025) 3,264,692 2,171,480
Other current assets 112,600 113,173
Total current assets 4,615,751 5,000,064
Property and equipment, net 14,865 12,056
Operating lease right-of-use assets 87,078 89,021
Investments measured at fair value 283,814 302,939
Other assets 31,094 32,860
Total assets 5,032,602 5,436,940
Current liabilities:    
Accounts payable 11,550 23,691
Accrued expenses 88,728 114,294
Operating lease liabilities 9,402 9,842
Other current liabilities 4,186 1,584
Total current liabilities 113,866 149,411
Liability instruments measured at fair value 12,310 9,981
Operating lease liabilities, noncurrent 90,292 90,328
Other liabilities 228 22
Total liabilities 216,696 249,742
Commitments and contingencies (Note 11)
Shareholders’ equity:    
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 682,229,832 and 695,938,323 shares issued and outstanding at June 30, 2025 and March 31, 2025, respectively 0 0
Additional paid-in capital 4,644,085 4,562,107
(Accumulated deficit) / retained earnings (315,588) 116,060
Accumulated other comprehensive income 17,137 9,438
Shareholders’ equity attributable to Roivant Sciences Ltd. 4,345,634 4,687,605
Noncontrolling interests 470,272 499,593
Total shareholders’ equity 4,815,906 5,187,198
Total liabilities and shareholders’ equity $ 5,032,602 $ 5,436,940